Multiple Myeloma | Meet The Professors: Management of Multiple Myeloma

published 3 weeks ago by Dr Neil Love

Featuring a roundtable discussion Drs Sergio A Giralt, Jonathan L Kaufman and Peter Voorhees, including the following topics: Case: A woman in her mid-70s with newly diagnosed multiple myeloma (MM) and trisomy in chromosomes 3, 9 and 11 — Neil Morganstein, MD (0:00) Role of autologous stem cell transplant (ASCT) in the management of MM; minimal residual disease (MRD) assessment and the impact of MRD negativity on outcomes (3:04) Use of proteasome inhibitors as maintenance therapy for MM; recommendations for patients with MM requiring an ASCT during the COVID-19 pandemic (11:09) Management of newly diagnosed MM; efficacy of ixazomib as maintenance therapy (17:41) Results of the GRIFFIN trial of daratumumab, lenalidomide, bortezomib and dexamethasone for patients with newly diagnosed MM who are eligible for transplant (22:22) Case: A woman in her early 70s with relapsed MM and compromised renal function — Ranju Gupta, MD (27:56) Case: A man in his early 40s with MM with 17p deletion and t(4;14) translocation — Lyle Feinstein, MD (34:47) Case: A man in his mid-60s with relapsed t(11;14) MM receives RVd (lenalidomide/bortezomib/dexamethasone) followed by a tandem transplant — Dr Morganstein (41:17) Efficacy of venetoclax-based regimens for patients with relapsed t(11;14) MM (43:28) Benefits and risks with selinexor or belantamab mafodotin for relapsed/refractory MM (49:55) Activity and tolerability of chimeric antigen receptor T-cell therapy and of bispecific antibodies in patients with MM (59:44) CME information and select publications

more episodes from Research To Practice | Oncology Videos